Wave Life Sciences Stock News

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, March 3, 2022, to discuss its fourth quarter and full year 2021 financial results and provide a business update.

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET.

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl

The Alzheimer''s Drug Discovery Foundation ((ADDF)) and the Association for Frontotemporal Degeneration ((AFTD)) have partnered to support Wave Life Sciences'' <> FOCUS-C9 phase…

Wall Street brokerages expect Wave Life Sciences Ltd. (NASDAQ:WVE) to announce earnings per share of ($0.47) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Wave Life Sciences earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.72). Wave Life Sciences posted []

Zacks Investment Research upgraded shares of Wave Life Sciences (NASDAQ:WVE) from a sell rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports. According to Zacks, WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntingtons disease, Duchenne muscular []

Wave Life Sciences Ltd. (NASDAQ:WVE) Equities researchers at Truist Securiti issued their Q1 2022 earnings per share (EPS) estimates for Wave Life Sciences in a research report issued to clients and investors on Wednesday, November 10th. Truist Securiti analyst J. Lee anticipates that the company will post earnings of ($0.66) per share for the []

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl

Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for c

Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing

Wave Life Sciences Ltd (NASDAQ: WVE) presented new preclinical data for its ADAR-mediated RNA editing capability (ADAR editing) and an update on its discovery-stage alpha-1 antitrypsin deficiency (

Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months

CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people batt